Table 1.
Demographic, disease and treatment characteristics of the participants (n=166)
| Variable | Value | |
|---|---|---|
| Age (years) | ||
| Mean (SD) | 51.3 (9.6) | |
| Range | 31 – 80 | |
| BMI (kg/m2) | ||
| Mean (SD) | 28.2 (7.0) | |
| Range | 17.4 – 61.9 | |
| Race [n (%)] | ||
| Caucasian | 133 (80.1) | |
| Non-Caucasian | 33 (19.9) | |
| Education [n (%)] | ||
| Some or completed high school | 29 (17.5) | |
| Some college | 53 (31.9) | |
| Completed college and above | 84 (50.6) | |
| Marital status [n (%)] | ||
| Never married | 13 (7.8) | |
| Divorced/separated/widowed | 38 (22.9) | |
| Married | 115 (69.3) | |
| Household annual income [n (%)] | ||
| ≤ $30,000 | 25 (15.1) | |
| > $30,000 | 119 (71.7) | |
| Refused to answer | 22 (13.2) | |
| Menopausal status [n (%)] | ||
| Baseline | pre-menopause | 65 (41.7) |
| peri-menopause | 16 (10.3) | |
| post-menopause | 52 (33.3) | |
| hysterectomy | 23 (14.7) | |
| Not available | 10 | |
| Cycle 4 Week 3 | pre-menopause | 7 (4.9) |
| peri-menopause | 28 (19.6) | |
| post-menopause | 85 (59.4) | |
| hysterectomy | 23 (16.1) | |
| Not available | 23 | |
| Cancer stage [n (%)] | ||
| Stage I | 40 (27.8) | |
| Stage II | 66 (45.8) | |
| Stage III | 38 (26.4) | |
| Not available | 22 | |
| Surgery type | ||
| Lumpectomy | 60 (41.7) | |
| Mastectomy | 65 (45.1) | |
| Double mastectomy | 8 (5.6) | |
| No surgery before Chemotherapy | 11 (7.6) | |
| Not available | 22 | |
| Chemotherapy regimen [n (%)] | ||
| AC | 38 (26.4) | |
| AC + docetaxel | 34 (23.6) | |
| AC + paclitaxel | 45 (31.2) | |
| AC + fluorouracil | 4 (2.8) | |
| Other | 23 (16.0) | |
| Not available | 22 | |
| Chemotherapy cycle length [n (%)] | ||
| 3-week | 116 (75.3) | |
| 2-week | 38 (24.7) | |
| Not available | 12 | |
Note: AC = Doxorubicin + Cyclophosphamide, ECF = Epirubicin + Cytoxan + Fluorouracil